Valeant Pharmaceuticals Management Is Doing Commendable Job But Key Challenges Remain, Says BTIG


Valeant Pharmaceuticals (NYSE:VRX) is on the road to redemption after a robust third quarter earnings showcase has seen the company gain around 10% in value in the past two days. BTIG analyst¬†Tim Chiang¬†calls the comeback kid of the Street’s leadership simply stellar, but says glaucoma drug Vyzulta needs to succeed.

Story Continues